Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thoracic Neoplasms 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × TNFSF10 protein, human × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡